Patients with adult minimal change nephrotic syndrome treated with long-term cyclosporine did not experience a reduction in their eGFR
- Resource Type
- Authors
- Yasuhiro Ando; Shigeaki Muto; Yoshiaki Hamano; Makoto Inoue; Chiharu Ito; Eiji Kusano; Wako Yumura; Yoshiyuki Morishita
- Source
- Clinical nephrology. 79(2)
- Subject
- Adult
Male
medicine.medical_specialty
Urology
Renal function
Elevated blood
Internal medicine
medicine
Secondary Prevention
Humans
In patient
Liver damage
Adverse effect
medicine.diagnostic_test
business.industry
Nephrosis, Lipoid
General Medicine
Middle Aged
Endocrinology
Nephrology
Prednisolone
Minimal change nephrotic syndrome
Cyclosporine
Female
Renal biopsy
business
Immunosuppressive Agents
medicine.drug
Glomerular Filtration Rate
- Language
- ISSN
- 0301-0430
BACKGROUND: The long-term efficacy and safety of cyclosporine (CyA) in the treatment of adult minimal change nephrotic syndrome (MCNS) was examined. METHODS: The medical record of 15 patients diagnosed with MCNS by renal biopsy and treated with CyA for at least 2 years were reviewed. RESULTS: The mean administration period of CyA was 78.3 months. The mean CyA dose for the induction period was 2.1 ± 0.9 mg/kg and 1.7 ± 1.0 mg/kg for the maintenance period. The mean dose of prednisolone used during the induction period was 20.3 mg and 2.7 mg during the maintenance. The frequency of MCNS relapse was decreased to 0.5 times/year in patients treated with CyA, compared to treatment without CyA (2.4 times/y). Two cases of mild liver damage and 3 cases of elevated blood pressure were observed during the administration of CyA. These adverse effects improved after reducing the CyA dose or treatment with an antihypertensive agent. A decrease in the estimated glomerular filtraion rate (eGFR) was not associated with long-term CyA use. CONCLUSION: At our institution, patients who were treated for MCNS with CyA for at least 2 years experienced no deterioration in renal function.